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Tato diplomová práce se zaměřila na popis diabetes mellitus z hlediska patogeneze, 
rizikových komplikací, farmakologické a nefarmakologické léčbě. 
 
Kormě toho jsme se v této diplomové práci také zaměřili na vztah diabetes mellitus a 
Alzheimerova nemoc. U tohoto stavu dochází k poruchám metabolizmu cukru, čím dochází k 
















This theses on Diabetes Mellitus aims at giving an insight at various aspects of this 
chronic disease and the risk factors that lead to it; the varius ways it develops in the human body; 
the old and new approaches to treatment, both from a pharmacological and a non-
pharmacologiacal point of view; ways to prevent and to manage the diabetes complications; how 
to improve the live of the diabetic patients who are faced with not only physical but also 
psychological problems; statistical data from around the world wkich focuses on epidemiology 
and outlines the issue of the cost of diabetes. 
Finally, this paper links diabetes mellitus with the Alzheimer’s disease as a different 
expression of diabetes, since it is closely associated with several key neuronal factors 
implicated in dementia. 
In many respects, Alzheimer’s is a brain form of diabetes. Even in the earliest stages of 
the disease, the brain’s ability to metabolize sugar is reduced. Normally, insulin plays a big role in 
helping the brain take up sugar from the blood. But, in Alzheimer’s, insulin is not very effective in 
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Diabetes mellitus, or simply diabetes, is a group of diseases characterized by high 
blood glucose levels that result from defects in the body's ability to produce and/or use 
insulin.  
It is a condition primarily defined by the level of hyperglycaemia giving rise to 
risk of microvascular damage (retinopathy, nephropathy and neuropathy). It is associated 
with reduced life expectancy, significant morbidity due to specific diabetes related 
microvascular complications, increased risk of macrovascular complications (ischaemic 
heart disease, stroke and peripheral vascular disease), and diminished quality of life 
(www.who.int/diabetes). 
Several pathogenetic processes are involved in the development of diabetes. These 
include processes, which destroy the beta cells of the pancreas with consequent insulin 
deficiency,and others that result in resistance to insulin action. The abnormalities of 
carbohydrate, fat and protein metabolism are due to deficient action of insulin on target 
tissues resulting from insensitivity or lack of insulin (Report of a WHO Consultation, 
1999).  
Diabetes mellitus may present with characteristic symptoms such as thirst, 
polyuria, blurring of vision, and weight loss. Often symptoms are not severe, or may be 
absent.  
1.2 History 
For 2,000 years diabetes has been recognized as a devastating and deadly disease. 
In the first century A.D. a Greek physician, Aretaeus, described the destructive nature of 
the affliction, which he named "diabetes" from the Greek word for "siphon" 
(www.diabeteshealth.com). Physicians in ancient times, like Aretaeus, recognized the 
symptoms of diabetes but were powerless to treat it effectively.  
In the 17
th
century a London physician, Dr. Thomas Willis, determined whether his 
patients had diabetes or not by sampling their urine. If it had a sweet taste he would 
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diagnose them with diabetes mellitus-"honeyed" diabetes. This method of monitoring 
blood sugars went largely unchanged until the 20th century.  
Before the discovery of the insulin little could be done for patients suffering from 
diabetes. Low calorie diets prolonged their lives but left them weak and near starvation. 
But in 1921, doctors in Canada treated patients dying of diabetes with insulin and 
managed to drop high blood sugars to normal levels. Since then, medical breakthroughs 
have continued to prolong and ease the life of people with diabetes.  
In the ’50s, it was discovered that there were two types of diabetes: "insulin 
sensitive" (type I) and "insulin insensitive" (type II).  
Two thousand years have passed since Aretaeus spoke of diabetes as "the 
mysterious sickness". It has been a long and arduous process of discovery, as generations 
of physicians and scientists have added their collective knowledge to finding a cure. It 
was from this wealth of knowledge that the discovery of insulin emerged in a small 
laboratory in Canada. Since then, medical innovations have continued to make life easier 
for people with diabetes.  
In the 21
st 
century, diabetes researchers continue to pave the road toward a cure. 
Today, it is unclear what shape the road will take; perhaps another dramatic discovery like 
insulin waits around the corner, or possibly researchers will have to be content with the 
slow grind of progress (Satley, 2008).  
1.3 Pathophysiology 
An understanding of the pathophysiology of diabetes rests upon knowledge of the 
basics of carbohydrate metabolism and insulin action. Following the consumption of food, 
carbohydrates are broken down into glucose molecules in the gut. Glucose is absorbed 
into the bloodstream elevating blood glucose levels. This rise in glycemia stimulates the 
secretion of insulin from the beta cells of the pancreas. Insulin is needed by most cells to 
allow glucose entry. Insulin binds to specific cellular receptors and facilitates entry of 
glucose into the cell, which uses the glucose for energy. The increased insulin secretion 
from the pancreas and the subsequent cellular utilization of glucose results in lowering of 
blood glucose levels. Lower glucose levels then result in decreased insulin secretion.  
If insulin production and secretion are altered by disease, blood glucose dynamics 
will also change. If insulin production is decreased, glucose entry into cells will be 
inhibited, resulting in hyperglycaemia. The same effect will be seen if insulin is secreted 
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from the pancreas but is not used properly by target cells. If insulin secretion is increased, 
blood glucose levels may become very low (hypoglycemia) as large amounts of glucose 
enter tissue cells and little remains in the bloodstream.   
Multiple hormones may affect glycemia. Insulin is the only hormone that lowers 
blood glucose levels. The counter-regulatory hormones such as glucagon, catecholamines, 
growth hormone, thyroid hormone, and glucocorticoids all act to increase blood glucose 
levels, in addition to their other effects (Meley et al, 2006). 
1.4 Complications 
Complications due to diabetes are a major cause of disability, reduced quality of 
life, and death. Diabetes complications can affect various parts of the body manifesting in 
different ways for different people. Diabetes increases patients’ risk for many serious 
health problems. In men, it is responsible for erectile dysfunction, low testosterone levels 
and emotional factors –such as depression, anxiety or stress–that can interfere with sexual 
feelings. In women, diabetes can be especially hard. Even those who do not have diabetes, 
pregnancy brings the risk of gestational diabetes. According to statistics from the 
American Diabetes Association, heart disease is the leading cause of death in women with 
diabetes(www.diabetes.org/living-with-diabetes). In addition, women with diabetes are 
afflicted by depression, their sexual health is at risk and eating disorders tend to occur 
more frequently.  
Diabetes can affect every part of the body, including the feet, the eyes and the 
skin.In fact, such problems are sometimes the first sign that a person has diabetes. Foot 
complications can get worse and lead to serious complications, such as neuropathy, skin 
changes, calluses as well as foot ulcers, poor circulation and (Aalto, 1997). 
1.5 Diagnosis 
The diagnosis of diabetes mellitus is easily established when a patient presents the 
classic symptoms of hyperglycaemia and has a random blood glucose value of 200 mg/dL 
(11.1 mmol/L) or higher, and confirmed on another occasion. 
The following tests are used for the basic diagnosis: 
A fasting plasma glucose (FPG) test measures blood glucose in a person who has 
not eaten anything for at least 8 hours. This test is used to detect diabetes and prediabetes. 
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An oral glucose tolerance test (OGTT) measures blood glucose after a person fasts 
at least 8 hours and 2 hours after the person drinks a glucose-containing beverage. This 
test can be used to diagnose diabetes and prediabetes. The FPG test is the preferred test 
for diagnosing diabetes because of its convenience and low cost. However, it may miss 
some diabetes or prediabetes that can be found with the OGTT. The FPG test is most 
reliable when done in the morning. Research has shown that the OGTT is more sensitive 
than the FPG test for diagnosing prediabetes, but it is less convenient to administer.  
A random plasma glucose test, also called a casual plasma glucose test, measures 
blood glucose without regard to when the person being tested last ate. This test, along 
with an assessment of symptoms, is used to diagnose diabetes but not prediabetes. 
Test results indicating that a person has diabetes should be confirmed with a 
second test on a different day (Twillman, 2002). 
The current WHO diagnostic criteria for diabetes should be maintained – fasting 
plasma glucose ≥ 7.0mmol/l (126mg/dl) or 2–h plasma glucose ≥ 11.1mmol/l (200mg/dl) 
(Report of a WHO Consultation, 1999). 
1.6 Types of diabetes mellitus 
The first widely accepted classification was published by the WHO in 1980 
(Second Report, 1980). Two major classes of diabetes mellitus were proposed: IDDM 
(Type I) and NIDDM (Type II). Other types as well as gestational diabetes were also 
included. The modified form of 1985 (Diabetes Mellitus: Report of a WHO Study Group, 
1985) was widely accepted and is used internationally.It was recommended that the terms 
“insulin-dependent diabetes mellitus” and “non-insulin-dependent diabetes mellitus” 
should no longer be used, because patients were classified according to treatment rather 
than pathogenesis. The terms Type I and Type II were introduced to describe the cases 
which are primarily due to pancreatic islet beta-cell destruction the former and the 
common major form of diabetes resulting from defects in insulin secretion the latter 
(Goodpaster, 2010). 
1.6.1 Type I Diabetes 
Type I accounts for only about 5—10% of all cases of diabetes; however, its 
incidence continues to increase worldwide and it has serious short-term and long-term 
implications. Type I indicates the process of beta-cell destruction in the pancreas that may 
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ultimately lead to diabetes mellitus in which “insulin is required for survival” to prevent 
the development of ketoacidosis, coma and death (Definition, Diagnosis and 
Classification of Diabetes Mellitus and its Complications.  Report of a WHO 
Consultation, 1999). 
Management of Type I diabetes is best undertaken in the context of a 
multidisciplinary health team and requires continuing attention to many aspects, including 
insulin administration, blood glucose monitoring, meal planning, and screening for 
diabetes-related complications. These complications consist of microvascular and 
macrovascular disease, which account for the major morbidity and mortality associated 
with Type I diabetes (Daneman, 2006). 
1.6.2. Type II Diabetes  
Type II is the most common form of diabetes. Millions of people around the world 
have been diagnosed with Type II diabetes, and many more remain undiagnosed. People 
with diabetes are at a greater risk of developing cardiovascular diseases such as heart 
attack and stroke if the disease is left undiagnosed or poorly controlled. They also have 
elevated risks for sight loss, foot and leg amputation due to damage to the nerves and 
blood vessels, and renal failure requiring dialysis or transplantation (Pasinetti, 2011). 
Before people develop Type II diabetes, they almost always have "prediabetes" –
bloodglucose levels that are higher than normal but not yet high enough to be diagnosed 
as diabetes. Recent research has shown that some long-term damage to the body, 
especially the heart and circulatory system, may already be occurring during 
prediabetes(DePaula, 2008). 
In Type II diabetes, either the body does not produce enough insulin or the cells 
ignore it. Insulin is necessary in order for the body to be able to use glucose for energy. 
After food consumption, the body breaks down all sugars and starches into glucose, which 
is the basic fuel for the cells. Insulin takes the sugar from the blood into the cells. When 












Figure 1: Estimated total prevalence of diabetes in people aged 20 years or older, by age group  
Source: National Health and Nutriton Examination, 


















1.6.3 Prevention / Delay of Type II Diabetes 
Before people develop Type II diabetes, they almost always have "prediabetes" –
blood glucose levels that are higher than normal but not yet high enough to be diagnosed 
as diabetes. Prediabetes is a serious medical condition that can be treated. A recently 
completed study carried out by scientists in the United States conclusively showed that 
people with prediabetes can prevent the development of Type II diabetes by making 
changes in their diet and by increasing their level of physical activity. They may even be 
able to bring their blood glucose levels back to the normal range. 
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Lifestyle changes are of outmost importance. A balanced diet and an increase of 
the level of physical activity can help maintain a healthy weight, stay healthier for longer 
and reduce the risk of diabetes. The results of the Diabetes Prevention Program (DPP) 
proved that weight loss through moderate diet changes and physical activity can delay or 
prevent Type II diabetes (Haus, 2010). The Diabetes Prevention Program (DPP) was a 
major multicenter clinical research study aimed at discovering whether modest weight 
loss through dietary changes and increased physical activity or treatment with the oral 
diabetes drug metformin (Glucophage) could prevent or delay the onset of type II diabetes 
in study participants. 
1.6.4 Diabetes in Pregnancy (Gestational Diabetes) 
Gestational diabetes is diabetes found for the first time when a woman is pregnant. 
Women who are overweight, have had gestational diabetes before or have a strong family 
history of diabetes are at a higher risk of developing gestational diabetes. Untreated 
gestational diabetes may cause problems to the baby. Both the mother and the baby are at 
increased risk for Type II diabetes for the rest of their lives (Harris, 1991). 
1.7 Risk factors 
There are controllable risk factors associated with diabetes, including obesity and 
an inactive lifestyle. However, other uncontrollable risk factors, such as ethnicity and 
genetics, also play a dramatic role. 
The primary risk factor for type I diabetes is a family history of this lifelong, 
chronic disease.Having family members with diabetes is a major risk factor. The 
American Diabetes Association (Standards of medical care in diabetes-2007)recommends 
that anyone with a first-degree relative with type I diabetes –a mother, father, sister, or 
brother– should get screened for diabetes. A simple blood test can diagnose Type I 
diabetes. 
In addition, injury or diseases of the pancreas can inhibit its ability to produce 
insulin and lead to type I diabetes.A range of relatively rare infections and illnesses can 
damage the pancreas and cause Type I diabetes (Laakso, 1999). 
The risk factors associated with type II diabetes include obesity, diet and physical 
inactivity, increasing age, insulin resistance, family history of diabetes, genetic factors, 
and race and ethnicity. As concerns genetic factors, research has shown that certain gene 
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variations raise the risk of developing diabetes. These genes can be associated with 
insulin sensitivity in the body's tissues, decreased insulin production and an increased risk 
of obesity. Race and ethnicity, on the other hand, are responsible for higher levels of 
diabetes in certain ethnic groups including African Americans, Mexican Americans, 
American Indians, native Hawaiians and some Asian Americans. The above mentioned 
groups have an increased risk of diabetes and heart disease. This is partly due to higher 
rates of high blood pressure, obesity and diabetes in these populations. African Americans 
are also more likely than other ethnic groups to develop Type IIDiabetes (Boulton et al, 
2005). 
Although genes and ethnicity are risk factors for diabetes, they are not the sole 
determinants of whether someone develops the disease. Changes in diet and decreased 
physical activity related to rapid technological development and urbanisation have led to 
sharp increases in the numbers of people developing diabetes. 
A history of substance use has been reported as a significant factor associated with 
earlier age of onset of Type II diabetes. Illicit drug use has also been associated to it, 
according to research in the United States(Karlon et al, 2001).The most common drugs 
regularly used are marijuana and cocaine, while other illicit drugs (amphetamines, heroin, 
hallucinogens, and nonmedical inhalants) are regularly used by diabetic primary care 
patients (ibid). 
2. Old and new approaches to treatment 
Diabetes is now ranked as the sixth leading cause of death by disease in the U.S (National 
diabetes fact sheet,Atlanta2004). Its treatment as well as the management of diabetes-
related complications remains a top priority for governments worldwide, since the 
economic burden in 2007 alone exceeded $174 billion (Dall et al, 2007). 
2.1 Pharmacological treatment 
Old approaches to the treatment of this chronic progressive disease include diet 
modification and oral hypoglycemic medications, which have proven inadequate, while 
insulin therapy only solves the problem temporarily. Even with the newest pharmaco-
therapies, patients continue to develop macro- and microvascular complications. Diabetes 
is associated with increased cardiac- and stroke-related deaths, kidney failure, blindness, 
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and 60% of non-trauma lower-limb amputations (National diabetes fact 
sheet,Atlanta2004).  
Alternative treatments targeting different models of this disease require careful 
and responsible examination. As shown below, apart from insulin treatment, it is possible 
to gain diabetes control after gastrointestinal bypass surgeries. 
2.1.1 Insulin therapy 
Diabetes, being one of the primary causes of increased cardiovascular morbidity 
and mortality in Western countries, constitutes a large burden to health care systems in 
terms of both direct and indirect costs. Therefore, efficient glucose control (attainment of 
normal HbA1C, prandial and postprandial glucose levels) is essential to the prevention of 
the life-threatening complications of this disease.  
Insulin is a hormone that treats diabetes by controlling the amount of sugar 
(glucose) in the blood. When used as a medication, it is derived from either pork 
(porcine), beef (no longer available in the U.S.), or is genetically made to be identical to 
human insulin (Buysschaert, 2000). 
Patients with type I diabetes mellitus depend on external insulin (most commonly 
injected subcutaneously) for their survival because the hormone is no longer produced 
internally. Patients with type II diabetes mellitus are insulin resistant, have relatively low 
insulin production, or both; certain patients with Type II diabetes may eventually require 
insulin if other medications fail to control blood glucose levels adequately.  
There are many types of insulin used to treat diabetes. They are classified by how 
fast they start to work, when they reach their “peak” level of action (i.e. when the 
concentration of insulin in the blood is highest), and how long their effects last. 
The types of insulin include: 
 Rapid-acting insulin, which starts working within a few minutes and lasts for a 
couple of hours. 
 Regular- or short-acting insulin, which takes about 30 minutes to work and lasts 
for 3 to 6 hours. 
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 Intermediate-acting insulin, which takes 2 to 4 hours to work and its effects can 
last for up to 18 hours. 
 Long-acting insulin, which takes 6 to 10 hours to reach the bloodstream, but it 
can keep working for an entire day (Tuomilehto, 2001).  
Insulin for diabetes can be injected under the skin (subcutaneously) or into the vein 
(intravenously). Subcutaneous insulin injection continues to be the mainstay of therapy 
for all people with type I diabetes mellitus and the majority of individuals with type 
IIdiabetes mellitus. Insulin can be injected using a needle and syringe, a cartridge system, 
or prefilled pen systems. Insulin pumps are also available. 
The initial dose is calculated based on the patient’s weight and sensitivity to insulin, 
which varies from person to person. When given under the skin, insulin is typically taken 
so that two-thirds of the total daily dose is given in the morning and one-third of the total 
daily dose is given in the evening (Glasgow, 1999). 
2.1.2 Complications of the insulin therapy 
Diabetes mellitus is defined as a group of metabolic diseases characterized by 
hyperglycaemia, which when untreated can lead to long-term complications, including 
micro- and macrovascular complications. Tight glycaemic control with intensive insulin 
therapy has been suggested to reduce the risk of such complications in several diabetes 
populations; however, such an approach can also be associated with risks and challenges. 
The major side effects of insulin taken for diabetes include low blood sugar 
(hypoglycemia), hypertrophy (enlargement of the area of the body that has received too 
many insulin injections), and rash at the site of injection or over the entire body (rare). 
The symptoms of the most common complication, i.e. low blood sugar, include extreme 
hunger, fatigue, irritability, cold sweats, trembling hands, intense anxiety and a general 
sense of confusion. They might be the signs of an insulin overdose, a potentially 
dangerous complication with diabetes, which happens to many diabetic patients 
(Gkaliagkousi, 2007). Thankfully, most episodes related to insulin are avoidable if 
patients stick with a few simple rules. 
Diabetic ketoacidosis (DKA) is another insulin complication, which is the result of 
not taking enough insulin. In that case, excessive urination in response to high sugar 
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causes severe dehydration. At the same time, without enough insulin to allow sugar 
absorption, the body's cells act as if they are starving. Without insulin, patients with type I 
diabetes develop severely elevated blood sugar levels. This leads to increased urine 
glucose, which in turn leads to excessive loss of fluid and electrolytes in the urine. Lack 
of insulin also causes the inability to store fat and protein along with breakdown of 
existing fat and protein stores. This dysregulation results in the process of ketosis and the 
release of ketones into the blood. Ketones turn the blood acidic, a condition called 
diabetic ketoacidosis (DKA). Symptoms of diabetic ketoacidosis include nausea, 
vomiting, and abdominal pain. Without prompt medical treatment, patients with diabetic 
ketoacidosis can rapidly go into shock, coma, and even death (ibid). 
Diabetic ketoacidosis (DKA) can be caused by infections, stress, or trauma, all of 
which may increase insulin requirements. In addition, missing doses of insulin is also an 
obvious risk factor for developing diabetic ketoacidosis. Urgent treatment of diabetic 
ketoacidosis involves the intravenous administration of fluid, electrolytes, and insulin, 
usually in a hospital intensive care unit. Dehydration can be very severe, and it is not 
unusual to need to replace 6-7 liters of fluid when a person presents in diabetic 
ketoacidosis. Antibiotics are given for infections. With treatment, abnormal blood sugar 
levels, ketone production, acidosis, and dehydration can be reversed rapidly, and patients 
can recover remarkably well (www.medicinenet.com/diabetes_mellitus). 
Similar to DKA, hyperosmolar hyperglycemic nonketotic syndrome 
(HHNS)causes profound dehydration and can be life-threatening. It is an extremely 
serious complication that can lead to diabetic coma and even death in type II diabetes. 
Hyperosmolar hyperglycemic syndrome is much less common than DKA and tends to 
happen in older, obese patients with type II diabetes (Buysschaert, 2000). 
Once they occur, these insulin complications require hospitalization for treatment. 
The mainstays of treatment for both HHNS and DKA are the same: correction of fluid 
deficits, electrolyte imbalances, and hyperglycaemia. In addition, it is particularly 
important in HHNS to identify and correct the underlying trigger condition.Hyperosmolar 
hyperglycemic nonketotic syndrome is often masked by the precipitating condition and 
comorbidities; it must be actively sought and the precipitating condition should be 
identified and treated.  
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In addition, HHNS has a high mortality rate. The fluid deficit is double than seen 
in diabetic ketoacidosis. The insulin therapy should be continued until the patient’s mental 
status improves, hyperosmolality resolves, and the target glucose level is reached.  
2.1.3 Non-Insulin Diabetes Treatment 
There is a relatively new class of drugs called incretinmimetics, which mimic 
certain substances that can be found in the stomach and intestinal tract. These substances 
are normally released in response to food intake and signal the release of insulin from the 
pancreas. Since this reaction is reduced in people with type II diabetes, incretinmimetics 
work to stimulate insulin release and help lower blood sugar. The doctor may recommend 
incretinmimetics if a patient has not been able to adequately control their blood sugar with 
other types of treatment. These medications are taken by injection, either once or twice a 
day. 
For people with type II diabetes, medications called DPP-4 inhibitors can be taken 
alone or in combination with other diabetes medications. DPP-4 inhibitors prevent the 
breakdown of incretin hormones. In turn, the incretins can help their body produce insulin 
to lower elevated blood sugar levels (Gkaliagkousi, 2007). 
Oral Hypoglycemic Agents (oha) 
The term “oral hypoglycemic agent” can refer to any anti-diabetic medication. The 
following five categories will be presented in brief: Sulphonylureasand similar 
(secretagogues), Biguanides (sensitizers), Thiazolidindiones, Alpha glucosidaseinhibitors, 
and Incretineanalogues/agonists (Boulton, 2005). 
As concerns the mode of action of the secretagogues like sulphonylureas, they block 
the ATP-sensitive K+ channel and as a result they stimulate the insulin secretion. They 
are indicated to be the first choice once a patient is diagnosed with Type II Diabetes. The 
side effects include hypoglycaemia and disulfiram reaction, while its interaction is the 
competition for protein binding/metabolism/secretion. The first-generation agents include 
tolbutamide(Orinase), acetohexamide(Dymelor), tolazamide(Tolinase), and 
chlorpropamide(Diabinese); the second-generation agents include glipizide (Glucotrol), 
glyburide (Diabeta, Micronase, Glynase), and gliclazide(Diamicron); the third-generation 
agents include glimepiride(Amaryl). The Meglitinides are short acting secretagogues, 
similar to sulphonylureas. They also block the ATP-sensitive K+ and they open the Ca2 + 
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channels, thus stimulating insulin secretion. Their side effects include weight gain and 
hypoglycaemia.  
i. As concerns the mode of action of the sensitisers such as the Biguanides, they 
reduce the hepatic synthesis and the output of glucose, while they increase the 
insulin uptake in the skeletal muscle. They are actually antihyperglycaemic 
and not hypoglycaemic. They are indicated for Type II Diabetes Mellitus and 
polycystic ovary syndrome. They help reduce LDL cholesterol and triglyceride 
levels and they may help with the weight loss. Their side effects include 
lactate acidosis, GIT discomfort, diarrhea, renal toxicity, but they do not cause 
hypoglycemia. 
ii. As concerns the mode of action of the glitazones such as the Thiazolidinediones, 
they are selective agonists of PPARγ receptors, thus activating the insulin-
sensitive genes regulating the glucose and fat metabolism. As a result, they 
increase the insulin sensitivity in the periphereal tissue. Their side effects 
include hepatotoxicity (troglitazone).  
iii. As concerns the mode of action of the inhibitors of the alpha-glucosidase or the 
alpha amylace,they reduce the intestinal absorption of starch, dextrins, and 
disaccharides and as a result they reduce the postprandial plasma glucose. 
They are indicated both for Type I and Type II Diabetes, in combination with 
diet and insulin. Their side effects include malabsorption, flatulence, and 
diarrhea. 
iv. As concerns the mode of action of the peptide analogues such as the GLP-1 
agonists, they bind to a membrane GLP-1 receptor. They are metabolized by 
the dipeptidyl peptidase IV enzyme (DPP-IV). Their side effects include 
nausea, hypoglycemia (if given together with insulin secretagogue), and 
exenatide–acute pancreatitis. On the other hand, the mode of action of the 
GPP-4 inhibitors (gliptines) is that they increase the blood concentration of the 
incretin GLP-1 (glucagon-like peptide-1) by inhibiting its degradation by 
dipeptidylpeptidase-4 (DPP-4). It has fewer side effects than other OHA, but 





2.1.4 Metabolic surgery for type II diabetes 
Metabolic surgery is now emerging as an area dedicated to the establishment of 
surgical procedures specifically aimed at treating diabetes. In the early 1980s, surgeons 
realized that many patients with type II diabetes who had undergone gastric bypass for the 
treatment of morbid obesity experienced a complete diabetes remission. This remission 
proved durable (Porries et al, 1995). Diabetes control and remission seems to be best 
obtained with procedures that include an intestinal bypass, as in gastric bypass or 
biliopancreatic diversion. With a 14-year follow-up, Pories et al. (1995) found an 83% 
resolution of Type II Diabetes in 608 patients after gastric bypass. Remission is typically 
not seen until several months postoperatively, only once weight loss has occurred. 
The mechanism of diabetes resolution after gastrointestinal bypass remains 
unclear but is apparently not related to weight loss alone. In most cases, remission is 
observed in the days to weeks after surgery before any substantial weight loss has 
occurred (Briatore et al 2008). Furthermore, emerging evidence now shows that these 
effects may be achievable in the non-obese population as well.Clinical studies also show 
that the effect on diabetes after gastric bypass procedures does not depend only on the 
amount of weight loss (DePaula et al 2008).  
The surgical treatment of diabetes may be the answer to the global health crisis of 
the next generation. However, as with all other surgical procedures, the benefits of 
surgery must be weighed against the potential risks. In other words, one must consider the 
possible complications and mortality of surgery versus the probable remission of diabetes 
and decrease in lifelong diabetes-related morbidity and mortality. Contrary to commonly 
held misperceptions, bariatric surgery has a strikingly safe operative profile and 
associated low mortality (Rubino et al 2009). The benefits of diabetes resolution 
accomplished by surgery are significant. Diabetes-related mortality after Roux-en-Y 
gastric bypass has been followed over a period of 7 years and decreased 92% compared 
with controls (Adams et al 2007). Another benefit of the surgery is the general 
improvement in metabolic syndrome, which contributes to a decrease in cardiovascular 
risk factors. Studies have shown a significant improvement in all components of the 
metabolic syndrome (type II diabetes, hypertension, increased fasting glucose and 
triglycerides, decreased HDL, and abdominal obesity) and an overall resolution of 95.6% 
at 1 year (Rossi et al 2008).  
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Surgery seems to provide an additional weapon against diabetes. Despite the 
compelling outcome data, the decision to operate should be made based on a risk factor 
assessment for each patient. Surgery is by design an invasive treatment modality and 
carries risks related to both anesthesia and the procedure itself. The potential benefits of 
metabolic surgery are in fact enormous. However, its implementation requires a 
rethinking of diabetes treatments goals and strategies. In the meantime, investigation into 
the pathophysiological basis of diabetes continues, with the hope of discovering the 
optimal therapeutic targets and best-suited interventions. 
2.2 Non-pharmacological treatment 
When it comes to non-pharmacological treatment of diabetes mellitus –especially 
type II diabetes– lifestyle modification alone can prevent development of diabetes in 
impaired glucose tolerance patients. It can also be the sole therapeutic tool in early 
diabetes. 
After being diagnosed with diabetes, a behavior and lifestyle modification is 
required. Health care providers should advice all diabetics not to initiate tobacco and 
emphasize stopping smoking in smokers as utmost priority for diabetic smokers (Diabetes 
care 1993), since it increases the risk of renal failure, visual impairment, foot ulcers, leg 
amputations and heart attacks in people with diabetes. The effects of stopping smoking in 
diabetes are substantial. The incidence of micro and macro vascular complications was 
significantly increased in smokers compared to non-smokers (Buysschaert, 2000). 
As concerns alcohol, consumption of large amounts can cause hypoglycaemia and 
this can occur many hours after alcohol intake, particularly if no food has been consumed 
beforehand. 
2.2.1 Diet and Diabetes Mellitus 
The major environmental factors that lead to type II diabetes are sedentary lifestyle and 
over nutrition leading to obesity (Harris, 1991). Sedentary lifestyle is more common in 
urbanized societies. 
Dietary advice is essential upon diagnosis of diabetes. Normal advice includes: 
 reducing intake of fatty foods 
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 eating mainly vegetables, fruit, cereal, rice and pasta (using wholemeal 
products where 
 possible) 
 eating only small amounts of refined sugar (jam, sweets etc.) 
 eating at regular intervals 
 carrying glucose tablets, sweets or products in case of hypoglycaemia 
 exercising regularly; not only does it help reduce hyperglycaemia, but it also 
reduces insulin resistance by reducing obesity. 
Most cases are preventable with healthy lifestyle changes and some can even be 
reversed. Taking steps to prevent and control diabetes doesn’t mean living in deprivation. 
While eating right is important, patients don’t have to give up sweets entirely or resign 
themselves to a lifetime of “health food”.  
Carbohydrates have a big impact on your blood sugar levels –more so than fats 
and proteins. In general, patients should limit highly refined carbohydrates like white 
bread, pasta, and rice, as well as soda, candy, and snack foods. Focus instead on high-
fiber complex carbohydrates—also known as slow-release carbs. Slow-release carbs help 
keep blood sugar levels even because they are digested more slowly, thus preventing the 
body from producing too much insulin. They also provide lasting energy and help people 
stay full longer (Gross, 2005). 
2.2.2 Exercise and Diabetes Mellitus 
Physical activity reduces the risk of developing type II diabetes by 30-50% and 
risk reductions are observed with as little as 30 minutes of moderate exercise per day 
(Gkaliagkousi 2007). Regular exercise improves glycaemic control in all forms of 
diabetes. Insulin resistance is the major cause of hypoglycemia in type II diabetes and 
physical exercise is the best way to reduce insulin resistance (Goodpaster et al 2010). 
Physical activity improves insulin sensitivity in many ways. Fat accumulation in the liver 
is the main cause of insulin resistance in obesity. Exercise can reduce the free fatty acid 
load to liver and thereby reduce hepatic insulin resistance (Haus et al 2010). Exercise 
recommended is moderate exercise for 30 minutes a day (Tuomilehto et al 2001) or 
moderate physical activity like brisk walking at least 150 minutes per week (Diabetes 
Prevention Programme research group in NEJM 2002).  Putative protective mechanisms 
23 
 
include reduction of body weight; reduction of insulin resistance, and thereby the 
associated consequences of the metabolic syndrome, including hypertension, 
dyslipidaemia and inflammation; and enhancement of endothelial function (Gkliagkousi 
2007). 
There are further benefits from staying active apart from losing weight and 
keeping fit. According to the American Diabetes Association, physical activity improves 
glucose management, lowers blood pressure, improves blood fats, as well as reduce the 
amount of insulin or diabetic pills after losing weight. It also helps keep off the weight a 
person loses and lowers the risk for other health problems. Physically active people will 
soon discover that they gain more energy and get better sleep as a result of action, which 
also reduces stress, anxiety and depression. Physical activities build stronger bones and 
muscles and helps people of all ages stay more flexible (American Diabetes Association: 
Standards of medical care in diabetes-2007). 
2.2.3 Biological drugs in the therapy of Diabetes Mellitus 
Biological therapy is treatment designed to stimulate or restore the ability of the 
body's immune system to fight infection and disease. Biological therapy is also called 
biotherapy or immunotherapy. Biological drugs are defined as medicines the active 
substance of which comes from a biological source. 
These drugs are very different from normal prescription drugs and are developed 
through advanced technology called “genetic modification”. Most of the biological drugs 
today are monoclonal antibodies (mABs). They can fight disease in the same way normal 
antibodies do, but they have been specially changed to find the specific area that needs 
treatment and to treat a specific disease with fewer side effects (Hauset al, 2010). 
In type I diabetes, insulin-producing pancreatic β-cells are attacked and destroyed 
by the immune system. Although man-made insulin is life-saving, it is not a cure and it 
cannot prevent long-term complications. In addition, most Type I Diabetes patients would 
do almost anything to achieve release from the burden of daily glucose monitoring and 
insulin injection. Despite the formation of very large and promising clinical trials, a 
means to prevent and cure the disease in humans remains elusive.  
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This has led to an increasing interest in the possibility of using T cells with 
regulatory properties (Treg cells) as a biological therapy to preserve and restore tolerance 
to self-antigens (ibid). 
Type I Diabetes accounts for 5% of the diabetic cases. Patients can no longer 
produce their own insulin either as a result of the destruction of the patient’s β-islet cells 
of the pancreas by autoreactive T-cells or due to the neutralizing effect of auto-antibodies 
directed against insulin. The only treatment option today is insulin replacement. 
An ActoBiotic developed by ActoGeniX is capable of delivering pro-insulin and 
IL10 in the gut, showing a restoration of antigen-specific, long-term tolerance and 
reversal of diabetes in NOD mice, combined with low-dose anti-CD3. Mechanistically, 
this intervention approach increases local regulatory T-cell frequencies, which proliferate 
in the pancreatic islets and suppress the auto-immune reaction in an antigen-specific way 
(ibid). Monoclonal antibodies, like Otelixizumab and Rituximab, can be used in the 
treatment of Type I Diabetes. 
Otelixizumab 
Otelixizumab, also known as TRX4, is a humanised anti-CD3 monoclonal 
antibody, which has been developed by Tolerx, Inc. as a treatment for autoimmune 
disorders, including Type I Diabetes. Otelixizumab targets CD3, a T lymphocyte receptor 
involved in normal cell signaling. It blocks the function of effector T cells, which 
mistakenly attack and destroy insulin-producing beta cells, while stimulating regulatory T 
cells, which are understood to protect against effector T cell damage, thus preserving the 
beta cells' normal ability to make insulin. 
In 2011, Otelixizumab failed in a pivotal Phase 3 study, leaving safety and 
efficacy issues of biological drugs open to speculation. Otelixizumab shows great promise 
but leaves room for improvement. Results of ongoing trials will help define its role in the 
prevention of T1DM (Goodpaster, 2010). 
Rituximab is a monoclonal antibody against the protein CD20, which is primarily 
found on the surface of β-cells.  It is used as a treatment to some autoimmune disorders, 
including Type I Diabetes. 
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Type I Diabetes is believed to be due to the autoimmune destruction of β-cells by 
T lymphocytes. It has been reported that a single course of Rituximab can attenuate C-
peptide loss over the first year of disease (Daneman, 2006). 
Biological drugs have been proven to help not only with the treatment of diabetes 
itself but also with the complications from which the patients suffer. In particular, they are 
used as a cure to diabetic foot ulcers and diabetic kidney disease. Therefore, patients can 
fight not only diabetes but other annoying issues as well. Prompt biological therapy has 
been proven to speed up diabetic foot ulcer healing. 
3. Prevention and management of diabetes complications 
Diabetes is a group of chronic diseases characterized by hyperglycaemia. Modern 
medical care uses a vast array of lifestyle and pharmaceutical interventions aimed at 
preventing and controlling hyperglycaemia. In addition to ensuring the adequate delivery 
of glucose to the tissues of the body, treatment of diabetes attempts to decrease the 
likelihood that the tissues of the body are harmed by hyperglycaemia.  
The importance of protecting the body from hyperglycaemia cannot be overstated; the 
direct and indirect effects on the human vascular tree are the major source of morbidity 
and mortality in both type I and type II diabetes.  
Diabetes complications are divided into two major categories: 
a. Acute complications such as hypoglycaemia and comas resulting either form DKA 
or HHNS (as stated above) and 
b. Chronic complications, either microvascular (diabetic retinopathy, nephropathy, 
neuropathy) or macrovascular (coronary artery disease, peripheral arterial disease, 
and stroke) 
Microvascular 
The most serious microvascular diabetes complications are the eye complications. 
Diabetic patients are strongly advised to have an annual ophthalmic exam. Diabetic 
retinopathy is the leading cause of blindness in the working population of the Western 
world. The risk of developing diabetic retinopathy or other microvascular complications 
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of diabetes depends on both the duration and the severity of hyperglycaemia (Almdal, 
2006). 
Diabetic retinopathy is generally classified as either background or proliferative. 
It is important to have a general understanding of the features of each to interpret eye 
examination reports and advise patients of disease progression and prognosis. Background 
retinopathy includes such features as small hemorrhages in the middle layers of the retina. 
They clinically appear as “dots” and therefore are frequently referred to as “dot 
hemorrhages.” Proliferative retinopathy is characterized by the formation of new blood 
vessels on the surface of the retina and can lead to vitreous hemorrhage (Watkins 2003). 
Diabetic nephropathy is the leading cause of renal failure in the United States. 
About 20% to 30% of the patients with diabetes develop evidence of nephropathy. Initial 
treatment of diabetic nephropathy, as of other complications of diabetes, is prevention. 
Like other microvascular complications of diabetes, there are strong associations between 
glucose control and the risk of developing diabetic nephropathy. Patients should be 
treated to the lowest safe glucose level that can be obtained to prevent or control diabetic 
nephropathy (Gross et al 2005). In addition to aggressive treatment of elevated blood 
glucose, patients with diabetic nephropathy benefit from treatment with antihypertensive 
drugs. Renin-angiotensin system blockade has additional benefits beyond the simple 
blood pressure-lowering effect in patients with diabetic nephropathy (Gross et al 2005). 
Diabetic neuropathy is recognized by the American Diabetes Association (ADA) 
as “the presence of symptoms and/or signs of peripheral nerve dysfunction in people with 
diabetes after the exclusion of other causes” (Diabetes Care 2007). As with other 
microvascular complications, risk of developing diabetic neuropathy is proportional to 
both the magnitude and duration of hyperglycaemia, and some individuals may possess 
genetic attributes that affect their predisposition to developing such complications.  
The precise nature of injury to the peripheral nerves from hyperglycaemia is not 
known but likely is related to mechanisms such as polyol accumulation, injury from 
AGEs, and oxidative stress. Peripheral neuropathy in diabetes may manifest in several 
different forms, including sensory, focal/multifocal, and autonomic neuropathies. More 
than 80% of amputations occur after foot ulceration or injury, which can result from 
diabetic neuropathy (Boulton et al 2005). 
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Diabetic autonomic neuropathy also causes significant morbidity and even 
mortality in patients with diabetes. Neurological dysfunction may occur in most organ 
systems and can by manifest by gastroparesis, constipation, diarrhea, anhidrosis, bladder 
dysfunction, erectile dysfunction, exercise intolerance, resting tachycardia, silent 
ischemia, and even sudden cardiac death ((Boulton et al 2005).Patientsmay be 
asymptomatic or complain of numbness, burning, tingling, and “electrical” pain. While 
the feet are mostly affected, the hands are seldom affected.  
Macrovascular 
The central pathological mechanism in macrovascular disease is the process of 
atherosclerosis, which leads to narrowing of arterial walls throughout the body. 
Atherosclerosis is thought to result from chronic inflammation and injury to the arterial 
wall in the peripheral or coronary vascular system (Lehto, 1996). 
Diabetes increases the risk that an individual will develop cardiovascular disease 
(CVD). Although the precise mechanisms through which diabetes increases the likelihood 
of atherosclerotic plaque formation are not completely defined, the association between 
the two is profound (Laing et al 2003). Cardiovascular disease is a major complication 
and the leading cause of premature death among diabetic patients(Merz et al 2002). 
Diabetic patients have a 2 to 6 times higher risk for developing complications such as 
ischemic heart disease, cerebrovascular disease and peripheral vascular disease than the 
general population.  
Among macrovascular diabetes complications, coronary heart disease has been 
associated with diabetes in numerous studies beginning with the Framingham study 
(Kannel et al 1979). 
The major cardiovascular risk factors in the non-diabetic population (smoking, 
hypertension and hyperlipidemia) also operate in diabetes, but the risks are enhanced in 
the presence of diabetes. Overall life expectancy in diabetic patients is 7 to 10 years 
shorter than non-diabetic people. 
Type II diabetes typically occurs in the setting of the metabolic syndrome, which 
also includes abdominal obesity, hypertension, hyperlipidemia, and increased 
coagulability. These other factors can also act to promote CVD. Even in this setting of 
multiple risk factors, type II diabetes acts as an independent risk factor for the 
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development of ischemic disease, stroke, and death (Almdal et al 2004), Diabetes is also a 
strong independent predictor of risk of stroke and cerebrovascular disease, as in coronary 
artery disease (Lehto et al 1996). 
The increased risk of CVD has led to more aggressive treatment of these 
conditions to achieve primary or secondary prevention of coronary heart disease before it 
occurs. Studies in Type I Diabetes have shown that intensive diabetes control is 
associated with a lower resting heart rate and that patients with higher degrees of 
hyperglycaemia tend to have a higher heart rate, which is associated with higher risk of 
CVD (Paterson et al 2007). 
Once clinical macro-vascular disease develops in diabetic patients they have a 
poorer prognosis for survival than normoglycaemic patients with macrovascular disease. 
The protective effects females have for the development of vascular disease are lost in 
diabetic females.  
In addition, the combination of hypertension and diabetes is a serious situation, 
posing increased predisposition to cardiovascular morbidity and mortality. There is no 
doubt that hypertension occurs more commonly in diabetic patients, and confer a greater 
prospect of development of complications; it should therefore be taken as seriously as 
glycaemic control when planning treatment strategies.  
Hyperlipidemia can occur as a result of poorly controlled diabetes, or may occur 
as an independent risk factor for macrovascular disease. About 25% of patients attending 
a diabetes clinic will have elevated lipid levels (Jacobson, 1985). 
Infections 
Diabetic patients are also in greater risk of infections than healthy individuals. The 
association between diabetes and increased susceptibility to infection in general is not 
supported by strong evidence. However, many specific infections are more common in 
diabetic patients and some occur almost exclusively in them. Other infections occur with 
increased severity and are associated with an increased risk of complications. 
Several aspects of immunity are altered in patients with diabetes. There is 
evidence that improving glycaemic control improves immune function. Fungal cystitis, 
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rhino-cerebral mucormycosis and community-acquired pneumonia are among the most 
common infections the diabetic patients suffer from (Gu, 1998). 
Recommendations for managing the complications of diabetes mellitus 
 Blood pressure should be measured routinely. Goal blood pressure is < 130/80 
mmHg. Patients with a blood pressure ≥ 140/90 mmHg should be treated with 
drug therapy in addition to diet and lifestyle modification. 
 Patients with a blood pressure of 130-139/80-89 mmHg may attempt a trial of 
lifestyle and behavioral therapy for three months and then receive 
pharmacological therapy if their goal blood pressure is not achieved. 
 Lipid testing should be performed in patients with diabetes at least annually. Lipid 
goals for adults with diabetes should be an LDL < 1000 mmol/l (or < 700mmol/l 
in patients with overt CVD), HDL > 500mmol/l, and fasting triglycerides < 
1500mmol/l. 
 All patients with diabetes should be encouraged to limit consumption of saturated 
fat, trans fat, and cholesterol. 
 Patients with type I diabetes should receive a comprehensive eye examination and 
dilation within 3-5 years after the onset of diabetes. Patients with type II diabetes 
should undergo such screening at the time of diagnosis. 
 Patients should strive for optimal glucose and blood pressure control to decrease 
the likelihood of developing diabetic retinopathy or experiencing progression of 
retinopathy (Paterson et al, 2007). 
 All patients with diabetes should undergo screening for distal symmetric 
polyneuropathy at the time of diagnosis and yearly thereafter. 
 Patients who experience peripheral neuropathy should begin appropriate foot self-
care, including wearing special footwear to decrease their risk of ulceration. 
 In addition to the above pharmacological recommendations, patients with diabetes 
should be encouraged to not begin smoking or to stop smoking to decrease their 
risk of CVD and benefit their health in other ways. 
4. Life with Diabetes Mellitus 
Diabetes affects over 24 million people in the United States today. It is a unique 
disease because people diagnosed with it must be responsible for the majority of their 
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own care. There are a lot of areas to cover. Insulin, medication, blood glucose monitoring, 
diet, and exercise are all important parts of diabetes management that must be 
incorporated into their lifestyle. There is not just one way of coping with the disease 
because it needs to be managed on a lot of different levels. Good diabetes management 
requires many different treatments and strategies in order to be effective.  
People experience a variety of feelings when they are first diagnosed with diabetes. 
Denial to accept that something is wrong, guilt of having caused the diabetes themselves 
or even anger are some of the most common reactions to the bad news.  
Diabetes is a common disease, yet every individual needs unique care 
(www.diabets.org/living-with-diabetes/treatment-and-care). The health care team is the 
point to start from. However, patients should always keep in mind that they themselves 
are the most important member of the health care team, which in turn depends on them to 
talk to them honestly and tell them how they feel or if they have noticed any problems.  
In general, treatment of diabetes aims to do what the body of a diabetic patient would 
normally do –maintain a proper balance of insulin and glucose. Living well with diabetes 
means keeping the level of glucose in the blood as close to normal as possible.  
The three elements for controlling type I diabetes are food, exercise and insulin. In 
many people with type II diabetes, diet and exercise alone can control blood glucose 
levels. A health care team will be able to suggest a specific lifestyle or exercise plan 
depending on age, lifestyle and overall health (Glasgow, 1999). 
The health care team 
The Primary Care Provider, who may be a primary care or family practice 
physician, is who the patients see for general checkups and when they get sick. Other 
health care providers who provide primary care include nurse practitioners and physician 
assistants, who typically work in collaboration with a physician (Diabetes Prevention 
Programme research group. Reduction in the incidence of type2 diabetes with life style 
intervensions or metformin. NEJM 2002) 
A nurse educator or diabetes nurse practitioner is a registered nurse (RN) with 
special training and background in caring for and teaching people with diabetes. Many are 
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certified in the field of diabetes. Nurse educators often help the patients learn the day-to-
day aspects of diabetes self-care (ibid). 
A registered dietitian (RD) is trained in nutrition but patients should make sure 
that the RD also has training and experience with diabetes. The RD helps patients figure 
out their food needs based on their desired weight, lifestyle, medication, and other health 
goals (such as lowering blood fat levels or blood pressure). Dietitians can also help 
patients learn how the foods they eat affect their blood sugar and blood fat levels (Laakso, 
1999). 
An endocrinologist is a doctor who specializes in treating diabetes and other 
diseases of the “endocrine system” –the body’s system of glands that produce hormones 
that control the way the body works. The pancreas is part of the endocrine system, and 
insulin is one of the key hormones the body needs to function properly. 
The eyedoctor is another key member of a patient’s health care team, because 
diabetes can affect the blood vessels in the eyes. When eye problems are caught early, 
there are very good treatments. The eye doctor will be either an ophthalmologist or an 
optometrist. The American Diabetes Association guidelines say you should see your eye 
doctor at least once a year. These checkups are the best way to detect diabetic eye disease 
(Rubin, 2000). 
Mental health professionals help with the personal and emotional side of living 
with diabetes. A few sessions with a psychologist might help during a time of special 
stress. On a long-term basis, a psychologist might help work on more lasting problems. A 
psychiatrist is a medical doctor who can prescribe medication to treat physical causes for 
emotional problems. Psychiatrists also provide counseling.  
A podiatrist is trained to treat feet and problems of the lower legs. Diabetes makes 
patients prone to poor blood flow and nerve damage in the lower legs. They may get 
infections more often. Sores, even small ones, can quickly turn into serious problems. 
Any foot sore or callus needs to be checked by a primary care doctor or a podiatrist. 
A pharmacist has a wealth of information on medicines: what’s in them and how 
they interact with each other. Pharmacists are highly trained professionals who must know 
about the chemistry of the products they dispense and what effects, both good and bad, 
medications have on the body. Therefore, they can also give advice on whether and how 
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any medication patients take for their diabetes or other conditions could or will affect 
their blood glucose levels. Pharmacists do more for diabetic patients than fill their 
prescriptions. They alert them to the potential common or severe side effects of any drug 
they are going to take. With each new prescription, they can review their medication 
profile to see if any of their current medications might interact with their new 
prescription. So, in addition to asking their diabetes care provider, diabetic patients can 
ask their pharmacist to recommend over-the-counter medicines for colds or other minor 
illnesses. For example, if a pharmacist knows that a diabetic patient takes a sulfonylurea, 
he or she may recommend a cold medicine with little or no alcohol to avoid any possible 
interaction between the two medications.  
Diabetic patients should visit a dentist every six months. People with diabetes are 
at somewhat greater risk for gum disease. The excess blood sugar in their mouths makes it 
a good home for bacteria, which leads to infection.  
An exercise physiologist is an indispensable part of a health care team when it 
comes to treat people with diabetes. Exercise plays a major role in diabetes care, either 
type I or type II diabetes, since it can help lower blood sugar, help the body better use 
insulin, and help control weight. It can also improve blood fat levels, reduce stress, and 
improve the overall fitness level. Diabetic patients should always get their doctor’s 
approval for any exercise programme. 
4.1 Quality of life 
Quality of life is also increasingly recognized as an important health outcome in 
its own right, representing the ultimate goal of all health interventions. More than 70 
years ago, the World Health Organization stated that health was defined not only by the 
absence of disease and infirmity, but also by the presence of physical, mental, and social 
well-being (World Health Organozation: Handbook of Basic Documents 1952). Though 
health care providers sometimes focus on medical outcomes alone when assessing the 
efficacy of their interventions, any person with diabetes will confess that these outcomes 
are truly meaningful only to the extent that they affect physical, emotional, and social 
well-being –thatis, quality of life. 
Diabetes is a demanding disease. Almost every diabetic person feels that diabetes 
powerfully affects their lives, and most feel burdened by the manifold demands of their 
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disease, an experience that could be called "diabetes overwhelmus," since so many people 
feel overwhelmed by the continuous burden of their disease and its management. These 
emotional and social burdens may be compounded by the acute physical distress of 
hypoglycaemia or hyperglycaemia and by the chronic physical distress of diabetes-related 
complications.   
It seems clear that diabetes can affect a person's quality of life. But what is quality 
of life? In the most general terms, quality of life may be thought of as a multidimensional 
construct incorporating an individual's subjective perception of physical, emotional, and 
social well-being, including both a cognitive component (satisfaction) and an emotional 
component (happiness) (Richard 2000).  
Quality of life has importance for people with diabetes and their health care 
providers for several reasons. Diabetes overwhelmus leads to diminished self-care, which 
in turn leads to worsened glycaemic control, increased risks for complications, and 
exacerbation of diabetes overwhelmus in both the short run and the long run.  
Some demographic variables are associated with quality of life in people with 
diabetes, just as they are in the general population:  
 Men generally report better quality of life than women. 
 Younger people generally report better quality of life than older people. 
 Those with more education or income generally report better quality of life than 
those with less of either. 
When it comes to quality of life for men with diabetes, sexual problems can be all 
too common. While both men and women can develop sexual problems because of 
damage to nerves and small blood vessels, men are much more affected. The National 
Diabetes Information Clearing House (NDIC) states that erectile dysfunction can range 
from 20% to as high as 75% of men with diabetes (www.diabetes.about.com). Men can 
also experience problems with ejaculation.  
All people encounter change in sexual function as they age. However, men with 
diabetes may start to experience problems at a younger age and with more severity due to 
small blood vessel and nerve damage caused by poor control of diabetes. Problems can 
appear as much as 10-15 years earlier than can be expected for men without diabetes. In 
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fact, erectile dysfunction in men younger than 45 years old can be a sign of diabetes or 
indicate a high risk for developing diabetes in the future.  
In order to lower the risk of sexual problems, men with diabetes should manage it 
very well, keep a healthy diet, exercise regularly as well as keep abdominal fat within 
normal limits. A health care provider may also suggest a treatment for erectile 
dysfunction but the first step is counseling and seeking out emotional and psychological 
support (Quality of Life -A population study, Diabetes Care 2004). 
4.2 Psychological factors and Diabetes Mellitus 
Any potentially life-threatening condition has some psychological impact, and that 
of diabetes is profound. In type I diabetes cases, family members often experience the 
classic stages of grief, progressing from anger and denial to bargaining, depression, and 
finally resolution or acceptance. 
The growing interest in health-related quality of life in general and diabetes-
related quality of life in particular is a positive trend, which reflects a deeper 
understanding and appreciation of the crucial role of behavioral and psychosocial factors 
in the lives of diabetic patients (Glasgow et al 1999). It is widely accepted that diabetes 
can affect a patient's quality of life, and that perceived quality of life can powerfully affect 
a person's commitment to active diabetes self-management. The growing awareness of the 
importance of quality of life in diabetes has led researchers to ask a broad range of 
questions concerning their interrelationships.  
Some psychosocial factors, including health-related beliefs, social support, coping 
style, and personality type might have a potent effect on quality of life. These effects may 
be direct, or they may be indirect, buffering the negative impact of diabetes or its 
demands. In fact, these psychosocial factors may be the most powerful predictors of 
quality of life, often outweighing the effects of important disease-related factors, such as 
complications (Peyrot et al 1999). 
Among adults, recent studies have shown that better Diabetes Related Quality of 
Life (DRQoL) is associated with higher levels of social support, self-efficacy, physical 
activity, education, income, and with the absence of health complications and co-morbid 
psychiatric disorders (Aalto et al 1997).  
35 
 
4.3 Depression and Diabetes Mellitus 
Depression 
The emotional well being of people with diabetes is important and is integral to 
the overall health of an individual, particularly for people with long-term conditions such 
as diabetes. People with diabetes may have emotional or psychological support needs 
resulting from living with diabetes or due to causes external to the condition. 
Coming to terms with diagnosis, the development of a complication, the side 
effects of medication, or dealing with the daily responsibility of self-managing diabetes 
can take their toll on emotional well-being. In some cases this can lead to depression, 
anxiety, eating disorders, or phobias. The prevalence of depression is approximately twice 
as high in people with diabetes as it is in the general population (Katon et al 2004). 
Diabetes self-management, especially type I, can be difficult and frustrating for 
both patients and practitioners. Thus, it is important to discuss psychosocial barriers to 
diabetes self-management and quality of life. Defining the meaning of psychological 
barriers is not easy. Webster’s dictionary defines a barrier as “something immaterial that 
impedes or separates” (Webster’s Encyclopedic Unabridged Dictionary of the English 
Language 1994). In the case of diabetes, researchers are concerned with psychological 
and interpersonal factors that impede diabetes management or diabetes-related quality of 
life. In this conceptualization, depression would be a barrier, due to its demonstrated 
inverse relationship to self-management and quality of life. 
People who are diagnosed with a chronic physical health problem such as diabetes 
are three times more likely to be diagnosed with depression than people without it 
(www.diabetes.co.uk/diabetes-and-depression). Depression can have a serious impact on 
a person's well being and their ability and motivation to self-manage their condition. 
Depression is the most common psychiatric disorder witnessed in the diabetes 
community. It may develop because of stress but also may result from the metabolic 
effects of diabetes on the brain (Kovacs et al 1995). Some studies have suggested that 
women with diabetes may be more likely to suffer from depression compared with their 
male counterparts (Wilkinson et al 1988). 
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For people with diabetes, dealing with a lifelong condition and managing the risk 
of complications can seem like an overwhelming task, particularly for newly diagnosed 
patients. Many diabetics struggle to cope with the requirements, feeling overwhelmed and 
unmotivated. If diabetes is not faced with an attitude of perseverance and defiance, often 
depression will prevail.  
Depression is associated with hyperglycaemia and an increased risk for diabetic 
complications; relief of depression is associated with improved glycaemic control. 
Depression has also been associated with an increased risk for complications of diabetes, 
particularly cardiovascular disease and retinopathy (Jacobson et al 1985). The 
mechanisms of these associations are not fully understood, but it is plausible that 
alleviation of depression improves glycaemic control and thereby decreases the risk for 
complications. Pharmacotherapy for depression may be poorly tolerated or may be 
insufficient to produce full remission in as many as 50% of diabetic patients with major 
depression (Popkin et al 1985). 
Depression for those with diabetes is an important comorbidity that requires 
careful management because of its severe impact on quality of life (Goldney et al 2004). 
Depression can affect a patient's capacity to deal with their diabetes, including managing 
blood glucose levels appropriately. Research has found that people who suffer from both 
diabetes and depression have poorer metabolic and glycaemic control which has, in turn, 
been found to intensify symptoms of depression (Lustman et al 2005). Treating 
depression with psychotherapy, medication or a combination of these treatments can 
improve a patient’s well-being and ability to manage diabetes (Ciechonowski et al 2000). 
Additionally, anti-depressants have been found to have hypoglycaemic effects 
causing serious problems for self-management. It has previously been reported that 
depressed people with diabetes are less likely to adherence to medication and diet 
regimens and subsequently have a reduction in quality of life and increased health care 
expenditure.Research has shown that by addressing depression, glycaemic control is 
enhanced, and mood and quality of life are significantly improved (Lustman et al 2005). 
Apart from depression, there are other mental health issues that can arise as a 
result of being diagnosed with a chronic physical condition such as diabetes. Conditions 




Managing the two conditions together 
Coping with the two conditions effectively can be a hard task. Patients are advised 
to adopt diabetes programmes that focus on behavior and they have been successful in 
helping people improve their metabolic control, increase fitness levels, and manage 
weight loss and other cardiovascular disease risk factors. They can also help improve the 
patients’ sense of well-being and quality of life. 
Furthermore, participants in psychotherapy, particularly cognitive behavioral therapy, 
have reported improvements in depression, which has resulted in better diabetes 
management. Psychotherapy is the principal non-pharmacologic method for the 
management of depression. Cognitive behavioral therapy identifies the indivindual’s 
thoughts (rather than external influences) as the cause of their feelings and actions. 
Therapists focus on altering the way patients think, in order to help them feel better 
(Wilkinson, 1988).    
5. Statistics 
Statistical data from around the world shows the prevalence of this disease. There 
is an emerging global epidemic of diabetes that can be traced back to rapid increases in 
overweight, obesity and physical inactivity. According to statistical data from the World 
Health Organisation, n developed countries most people with diabetes are above the age 
of retirement, whereas in developing countries those most frequently affected are aged 
between 35 and 64 (www.who.int).  
Prevalence of diabetes is increasing in the European Region, already reaching 
rates of 10-12% of the population in some Member States. This increase is strongly 
associated with increasing trends towards overweight and obesity, unhealthy diets, 
physical inactivity and socioeconomic disadvantage. These risk factors also contribute to 
the development of the other three noncommunicable diseases (NCDs) that have become 
international public health priorities (cardiovascular disease, chronic respiratory diseases 
and cancer), making it imperative that the prevention of diabetes be integrated into 
population approaches to prevent NCDs as a group (World Health Organization, 
Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications.  
Report of a WHO Consultation,1999). 
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The associated burden on a global level is increasing globally, particularly in 
developing countries. Noncommunicable diseases (NCDs), such as heart disease, stroke, 
cancer, chronic respiratory diseases and diabetes, are the leading cause of mortality in the 
world. This invisible epidemic is an under-appreciated cause of poverty and hinders the 
economic development of many countries.  
6. Type III Diabetes Mellitus 
New evidence has come to light concerning the different expressions of diabetes, 
as well as its connection to other diseases. It used to be thought that there were two types 
of diabetes: the type people are born with (Type I) and Type II, which was called ‘adult 
onset’ until it started ravaging chidren. Type II is brought about by a combination of 
factors, including diet. However, the idea that Alzheimer’s might be Type III diabetes has 
been around since 2006 (Martins, 2006). 
Over a century ago, aneuropathologist named Alois Alzheimer noticed that an odd 
form of protein was taking the place of normal brain cells. How those beta amyloid 
plaques (as they are called) get there has remained a mystery. What is becoming clear, 
however, is that a lack of insulin —or insulin resistance —not only impairs cognition but 
it also seems to be implicated in the formation of those plaques. 
Ever since this condition of clinical dementia was first described by Alois 
Alzheimer in1907, the incidence of Alzheimer’s Disease has increased exponentially. It is 
actually a progressive neurodegenerative disorder characterized by a progressive decline 
in memory functions. There are presently 5 million Americans affected with it, and the 
estimated annual health care cost is almost 100 billion dollars, which explains why it has 
become a growing public health concern. Furthermore, due to the expected increase in the 
number of individuals 65 years or older, it has been estimated that the total incidence of 
Alzheimer’s Disease will quadruple by the year 2050 (Brookmeyer et al 1998). 
It has recently been suggested that there is a linkbetween Alzheimer’s Disease and 
Type II Diabetes Mellitus (Pasinetti, 2011). Dr. Suzanne de la Monte from RIH is the one 
responsible for making this fascinating connection, having found in her research that 
diabetes is closely associated with several key neuronal factors implicated in dementia. It 
turns out that Alzheimer's progresses as a result of the brain developing resistance to 
insulin, which in turn prevents proper lipid (fat) metabolism. Over time, these lipids build 
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up in the brain rather than properly absorb, which results in increased stress and 
inflammation, as well as the symptoms commonly associated with dementia (Monte et al, 
2011). 
Suzanne de la Monte (ibid)has been working on these phenomena in humans and rats. 
When she blocked the path of insulin to rats’ brains, their neurons deteriorated, they 
became physically disoriented and their brains showed all the signs of Alzheimer’s. The 
fact that Alzheimer’s can be associated with low levels of insulin in the brain is the reason 
why increasing numbers of researchers have taken to calling it Type III diabetes, or 
diabetes of the (ibid). 
Emerging research on the widespread degenerative brain disease known as 
Alzheimer's suggests that this prevalent form of dementia is actually a type of diabetes. 
Published in the Journal of Alzheimer's Disease, a recent study out of Rhode Island 
Hospital (RIH) confirms that Alzheimer's is marked by brain insulin resistance and 
corresponding inflammation, a condition that some researchers are now referring to as 
Type III Diabetes (ibid). 
  In many respects, Alzheimer’s is a brain form of diabetes. Even in the earliest 
stages of the disease, the brain’s ability to metabolize sugar is reduced. Normally, insulin 
plays a big role in helping the brain take up sugar from the blood. But, in Alzheimer’s, 
insulin is not very effective in the brain. Consequently, the brain cells practically starve to 
death (Sun, 2011). 
These days, type II Diabetes Mellitus is the prevalent type of diabetes. Basically, 
cells throughout the body become resistant to insulin signals. In an effort to encourage 
cells to take up more sugar from the blood, the pancreas increases the output of insulin. 
The high levels of insulin could damage small blood vessels in the brain, and eventually 
lead to poor brain circulation. This problem could partly explain why Type II diabetes 
harms the brain. In Alzheimer’s, the brain, especially parts that deal with memory and 
personality, become resistant to insulin (ibid). 
As in most organs, insulin stimulates brain cells to take up glucose or sugar, and 
metabolize it to produce energy. In addition, insulin is very important for the chemicals 
known as neurotransmitters, which are needed for neurons to communicate with each 
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other. Insulin also stimulates many functions that are needed to form new memories and 
conquer tasks that require learning and memory (Pasinetti, 2011). 
People with diabetes are more likely to be diagnosed with Alzheimer’sDisease as 
well. In fact, their risk is doubled, at least. Obesity also increases the risk of cognitive 
impairment, or mental decline. This doesnot mean that everyone who has diabetes will 
develop Alzheimer’s in the long run or that all people with Alzheimer’s have diabetes.  It 
isimportant to recognise that there is considerable overlap between Alzheimer’s and 
diabetes. 
6.1 Shared pathophysiology between Type II Diabetes Mellitus and 
Alzheimer's disease                      
Diabetes and Alzheimer's disease have traditionally been thought to be 
independent disorders. However, the results of recent epidemiological and basic science 
investigation have suggested possible associations and some common pathophysiological 
mechanisms. If true, common pharmacotherapy should be effective. 
Type II Diabetes Mellitus and Alzheimer's disease are both more prevalent with 
ageing, but it has generally been assumed that this is coincidental, not a reflection of co-
morbidity. However, evidence suggests that patients with Type II Diabetes Mellitus are at 
an increased risk of getting Alzheimer’s Disease and that hyperinsulinaemia and insulin 
resistance –hallmarks of Type II Diabetes Mellitus– can lead to memory impairment 
(Akter et al 2011). 
Alzheimer's disease currently accounts for 60–80% of cases of dementia. Onset of 
symptoms progresses to cognitive decline and eventually leads to death. The exact 
pathological defects in Alzheimer’s Diseaseare unknown, but prevailing theories 
implicate build-up of soluble β-amyloid oligomers or insoluble plaques or neurofibrillary 
tangles (ibid). 
As concerns the role of insulin in Alzheimer’s Disease, insulin and insulin 
signaling have been suggested to play a role to its pathophysiology. In population-based 
studies, individuals with Type II Diabetes Mellitus are at an increased risk for cognitive 
impairment, dementia, and neurodegeneration. Mechanisms through which diabetes 
presents a risk factor include glycaemia, insulin resistance, oxidative stress, advanced 
glycationend-products, inflammatory cytokines, and microvascular and macrovascular 
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disease. The principal defect in Type II Diabetes Mellitus is insulin resistance, leading to 
insulin deficiency. The islet of Langerhans (in the pancreas) in Type II Diabetes is 
characterized by β-cell loss and islet amyloid derived from islet amyloid polypeptide 
(IAPP), a protein co-expressed and secreted with insulin by β-cells. As with Aβ peptides, 
IAPP spontaneously forms into amyloid aggregates in an aqueous environment. 
Additionally, as with Alzheimer’s Disease, the incidence of Type II Diabetes strongly 
increases with age. Borderline diabetes is also associated with increased risks of dementia 
and Alzheimer’s Disease, independent of whether one develops diabetes in later life, and 
may interact with severe systolic hypertension to multiply one's risk for Alzheimer's 
disease. These findings implicate a close biological relationship between Type II Diabetes 
and AD (Pasinetti et al 2011). 
 6.2 The link between Alzheimer’s Disease and Type II Diabetes Mellitus                                                    
Alzheimer's disease is a devastating neurodegenerative condition. There is much evidence 
suggesting that certain dietary lifestyles can help to prevent and possibly treat Alzheimer's 
disease.  
High-fat diets and sedentary lifestyles have become major concerns throughout the 
world. They have led to a growing incidence of obesity, dyslipidemia, high blood 
pressure, and hyperglycemic conditions, known collectively to be components of 
metabolic syndrome. These health conditions are well known to develop along with, or be 
precursors of, atherosclerosis, cardiovascular disease, and diabetes. Recent studies have 
found that most of these disorders can also be linked to an increased risk of the 
Alzheimer’s Disease. Of note, accumulating evidence suggests a mechanistic link 
between the cholesterol metabolism in the brain and the formation of amyloid plaques in 
AD development (Martins et al 2006). 
The risk for developing both Type II Diabetes Mellitus and sporadic Alzheimer’s 
Disease increases exponentially with age, and having Type II Diabetes Mellitus doubles 
the risk of developing Alzheimer’s Disease. The postmortem brains of Alzheimer’s 
Disease patients show altered activities of insulin receptors and downstream molecules, as 
well as reduced protein and mRNA levels of insulin (Monte et al, 2011). 
Morerecent laboratory research using animal models has identified mechanisms 
that are shared by diabetes and Alzheimer’s Disease. Exogenous application of 
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streptozotocin, which disrupts systemic insulin secretion, results in insulin deficiency, 
increased tau phosphorylation, and cognitive impairments that can be reversed by 
exogenous insulin supplementation ((Sun 2011). 
However, Alzheimer’s Disease pathology is more severe in Type II Diabetes 
Mellitus. The symptoms of this Alzheimer’sDisease pathology included increased tau 
phosphorylation at multiple sites, increased tau cleavage, and greater neuronal and 
synaptic damage, even with increased amyloid β protein production. Therefore, it has 
been suggested that hyperinsulinemia and insulin resistance represent major factors 
underlying Alzheimer’s Disease in Type II Diabetes Mellitus (Monte 2011). 
A recent study involving cross-mating ob/ob and amyloid precursor protein 
transgenic mice provided evidence that Type II Diabetes Mellitus and Alzheimer’s 
Diseaseaggravate each other, and suggested that cerebral vessels constitute an important 
substrate that is commonly damaged by the two major disorders. Given the evidence 
provided by animal models, further investigation of the mechanisms underlying Type II 
Diabetes Mellitus in Alzheimer’s Diseaseshould help to identify potential treatment 
targets in Alzheimer’s Disease (Sun 2011). 
Conclusions 
According to the World Health Organization, diabetes is a chronic disease, which 
occurs when the pancreas does not produce enough insulin, or when the body cannot 
effectively use the insulin it produces. This leads to an increased concentration of glucose 
in the blood (hyperglycaemia).Type I diabetes (previously known as insulin-dependent or 
childhood-onset diabetes) is characterized by a lack of insulin production.Type II diabetes 
(formerly called non-insulin-dependent or adult-onset diabetes) is caused by the body’s 
ineffective use of insulin. It often results from excess body weight and physical 
inactivity.Gestational diabetes is hyperglycaemia that is first recognized during 
pregnancy. 
It is essential to raise awareness about diabetes and its escalating rates around the 
world. That is the reason why the International Diabetes Federation and the World Health 
Organization started the International Diabetes Day. It is celebrated on 14
th
 November to 
mark the birthday of Frederick Banting who, along with Charles Best, was instrumental in 
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the discovery of insulin in 1922, a life-saving treatment for diabetes patients. (The 
information is provided at theofficial website of WHO). 
It is not easy for anyone to hear that they have diabetes. But for millions of people 
around the world, learning about their diabetes is the first step toward feeling better and 
living a longer, healthier life.However, the situation is not always irreversible. Lifestyle 
interventions including modified diet, increased physical activity, and weight loss are 
critical for all diabetes patients. For highly motivated patients, whose diabetes is at a 
relatively early stage, it is even possible to pursue lifestyle interventions for three to six 
months before starting medication. 
There are old and new approaches to the treatment of diabetes mellitus. Old 
approaches include diet modification and oral hypoglycemic medication. Insulin is a 
temporary solution to the problem. In addition, insulin therapy has serious complications, 
such as diabetic ketoacidosis etc. Non-insulin diabetes treatment engages incretin 
mimetics, which the substances found in the stomach and the intestinal tract as a response 
to food intake. Then, they signal the release of insulin from the pancreas. There are the 
oral hypoglycemic agents, such as sulphonylureas and similar (secretagogues), biguanides 
(sensitizers), thiazolidindiones, alpha glucosidaseinhibitors, and 
incretineanalogues/agonists. It is possible to undergo metabolic surgery, gastric bypass in 
particular. Biological drugs can also help fight diabetes mellitus.  
The complications of diabetes often lead to the death of most diabetic patients, 
since the risk for stroke and heart disease is much higher when compared to adults 
without diabetes. Diabetes can also lead to blindness, kidney disease, nervous system 
damage, infections, dental disease, and complications of pregnancy. It can also be a cause 
for amputations. There is also greater possibility for diabetic patients to have depression. 
Cosequently, it is important for them to invlve themselves in psychotherapy, which will 
not only help them with depression but it will also help with the management of diabetes. 
Apart from the diabetist and the psychotherapist, the health care team of diabetic patients 
should consist of  
The population of the developed world is aging, and the incidence of age-related 
metabolic and neurodegenerative diseases are increasing. Diabetes and Alzheimer disease 
—two age-related diseases— are both increasing in prevalence, and numerous studies 
have demonstrated that patients with diabetes have an increased risk of developing 
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Alzheimer’s Diseasecompared with healthy individuals. Both diseases are associated with 
enormous and increasing socio-economic effects. The co-existence of these two diseases 
in a society with an increasing mean age is a significant issue. However, it has generally 
been assumed that this co-existence is coincidental and not a reflection of co-morbidity. 
The underlying biological mechanisms that link the development of diabetes with 
Alzheimer’s Disease are not fully understood. Abnormal protein processing, 
abnormalities in insulin signaling, dysregulated glucose metabolism, oxidative stress, the 
formation of advanced glycation end products, and the activation of inflammatory 
pathways are features common to both diseases. Hypercholesterolemia is another factor 
that has received attention, owing to its potential association with diabetes and 
Alzheimer’s Disease. 
Much research has been conducted to reveal the mechanisms potentially linking 
Type II Diabetes Mellitus with cognitive impairment on the one hand and its link to 
Alzheimer’s Disease on the other. Alzheimer’s disease is one of the most common 
degenerative dementias, and more than 115 million new cases are projected worldwide in 
the next 40 years. There is clinical and experimental evidence that treatment with insulin 
or insulin sensitizer agents can enhance cognitive function and in some circumstances 
help slow the rate of cognitive decline in Alzheimer’s Disease. Alzheimer’s and other 
neurodegenerative diseases destroy the brain until the patients finally succumb. In order to 
effectively halt the process of neurodegeneration, the forces that advance and perpetuate 
the disease, particularly with regard to the progressive worsening of brain insulin/IGF 
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